GENE INTERACTIONS

Developing a taxonomy for colorectal cancer

Analyzing how gene interaction networks are perturbed in individuals can help identify different types of colorectal cancers, paving the way towards personalized care.

JIANSONG FANG, DAWEI WANG AND XIUDE FAN

Colorectal cancer is challenging to treat because different patients have widely varying symptoms and the cancers display a broad range of molecular characteristics (Guinney et al., 2015). What can researchers and clinicians do to overcome these obstacles? First, it is necessary to understand the biological properties that make each type of colorectal cancer different, and to establish a precise molecular classification for the different subtypes based on these differences. This will help researchers to develop effective drug interventions. In the past decade, many diseases have been classified based on their transcriptome. However, this ignores the fact that levels of gene expression can vary widely in living patients (Wang et al., 2019).

Now, in eLife, Zhenqiang Sun, Xinwei Han and colleagues at the First Affiliated Hospital of Zhengzhou University – including with Zaoqiu Liu as first author – report how they have developed a taxonomy for colorectal cancers based on the interactions between genes rather than on the levels of gene expression (Liu et al., 2022). This approach analyzes networks of gene interactions, which tend to be conserved in healthy samples, but are perturbed in cancer. This makes it possible to characterize the different types of tumors based on how their gene interaction networks are perturbed.

First, the researchers used a dataset including tumors and healthy samples to generate a large-scale network that had genes as the nodes of the network, and the interactions between genes as the edges. Next, for both healthy and cancerous samples, they quantified the level of perturbation by measuring how the interactions between each pair of genes in the network had changed. This analysis showed that the perturbations were much stronger in the tumors. Moreover, using a computational approach called clustering analysis, Liu et al. were able to establish six subtypes of colorectal cancers, which they called gene interaction-perturbation network subtypes (or GINS for short; Figure 1). Comparing this new taxonomy with previously published classifications of colorectal cancers revealed that there are notable differences between GINS and subtypes from other taxonomies (Figure 1). Liu et al. were able to confirm the stability and reproducibility of their proposed classification by validating it in independent datasets, which suggests that this taxonomy will be extremely useful for clinical applications.

A good molecular classification needs to convey clear biological interpretations of the underlying data, as this will help lay the ground for trials and treatments aimed at specific subtypes (Lin et al., 2021; Ten Hoorn et al.,
Figure 1. A new taxonomy for colorectal cancer.

Liu et al. identified six subtypes of colorectal cancer: GINS1 is a proliferative subtype (green); GINS2 is a stromal-rich subtype (yellow); GINS3 is a KRAS-inactivated subtype (grey); GINS4 is a mixed subtype (red); GINS5 is an immune-activated subtype (bright blue); and GINS6 is a metabolic reprogramming subtype (dark blue). Liu et al. report that GINS4 is an intermediate state between the GINS2 and GINS5 subtypes, which suggests that converting GINS4 into GINS5, which has a better prognosis and may be more sensitive to immunotherapy (especially to PARP inhibitors), might be a good treatment strategy. The GINS6 subtype, on the other hand, may respond well to statins based on its characteristics.

2022; Singh et al., 2021). Along these lines, Liu et al. report distinguishing features for each of the six subtypes they have identified. For example, GINS1 is a proliferative subtype, whereas GINS2 is a stromal-rich subtype; Figure 1 has details on the other four subtypes.

Looking forward, the new taxonomy will need to be validated by further studies in different populations. Additionally, the classification could be improved by integrating multi-omics data—such as transcriptomic data and proteomic data—into the network. In recent years, the HuRI and BioPlex initiatives have provided comprehensive human interactomes at the proteome level, improving our understanding of genotype-phenotype relationships (Luck et al., 2020; Huttlin et al., 2021). These could be used to make the new perturbation network more robust. Finally, it might also be possible to apply the new network to other challenges, for example, to identify new therapeutic agents for colorectal cancer through network-based approaches (Fang et al., 2021).

The work of Liu et al. is another example of the use of network-based approaches to classify cancer subtypes, such as the recent molecular taxonomy developed for meningioma (Nassiri et al., 2021). The results present and validate a new classification system for colorectal cancer, providing more insights into the heterogeneity of the disease, and facilitating both translational research and personalized approaches to treatment.

Jiansong Fang is in the Department of Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China
http://orcid.org/0000-0002-6998-5384

Dawei Wang is in the Department of Endocrinology, Shandong Provincial Hospital, Shandong University, Jinan, China
http://orcid.org/0000-0001-7902-001X

Xiude Fan is in the Department of Endocrinology, Shandong Provincial Hospital, Shandong First Medical University, Jinan, China
fanxiude@sdfmu.edu.cn

http://orcid.org/0000-0001-7413-080X

Competing interests: The authors declare that no competing interests exist.

Published 11 November 2022

References

Fang J, Zhang P, Zhou Y, Chiang CW, Tan J, Hou Y, Stauffer S, Li L, Pieper AA, Cummings J, Cheng F. 2021. Endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer’s disease. Nature Aging 1:1175–1188. DOI: https://doi.org/10.1038/s43587-021-00138-z, PMID: 36345721

Guiney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P, Bot BM, Morris JS, Simon IM, Gerster S, Fessler E, De Sousa E Melo F, Missiaglia E, Ramay H, Barras D, Homcisko K, et al. 2015. The consensus molecular subtypes of colorectal cancer. Nature Medicine 21:1350–1356. DOI: https://doi.org/10.1038/nm.3967, PMID: 26457759

Huttlin EL, Bruckner RJ, Navarrete-Perea J, Cannon JR, Baltier K, Gebreab F, Gygi MP, Thornock A, Zarraga G, Tam S, Szpyt J, Gassaway BM, Panov A, Parzen H, Fu S, Golbazi A, Maenpaa E, Stricker K, Guha Thakurta S, Zhang T, et al. 2021. Dual proteome-scale networks reveal cell-specific remodeling of the human interactome. Cell 184:3022–3040. DOI: https://doi.org/10.1016/j.cell.2021.04.011, PMID: 33967181

Lin D, Fan W, Zhang R, Zhao E, Li P, Zhou W, Peng J, Li L. 2021. Molecular subtype identification and prognosis stratification by a metabolism-related gene expression signature in colorectal cancer. Journal of Translational Medicine 19:279. DOI: https://doi.org/10.1186/s12967-021-02952-w, PMID: 34193202

Liu Z, Weng S, Dang Q, Xu H, Ren Y, Guo C, Xing Z, Sun Z, Han X. 2022. Gene interaction perturbation network deciphers a high-resolution taxonomy in colorectal cancer. eLife 11:e81114. DOI: https://doi.org/10.7554/eLife.81114, PMID: 36345721

Luck K, Kim D-K, Lambourne L, Sprirohn K, Begg BE, Bian W, Brignall R, Cafarelli T, Campos-Laborie FJ, Charloteaux B, Choi D, Coté AG, Daley M, Deimling S,
Desbuleux A, Dricot A, Gebbia M, Hardy MF, Kishore N, Knapp JJ, et al. 2020. A reference map of the human binary protein interactome. *Nature* **580**:402–408. DOI: https://doi.org/10.1038/s41586-020-2188-x, PMID: 32296183

Nassiri F, Liu J, Patil V, Mamatjan Y, Wang JZ, Hugh-White R, Macklin AM, Khan S, Singh O, Karimi S, Corona R, Liu LY, Chen CY, Chakravarthy A, Wei Q, Mehani B, Suppiah S, Gao A, Workewych AM, Tabatabai G, et al. 2021. A clinically applicable integrative molecular classification of meningiomas. *Nature* **597**:119–125. DOI: https://doi.org/10.1038/s41586-021-03850-3, PMID: 34433969

Singh MP, Rai S, Pandey A, Singh NK, Srivastava S. 2021. Molecular subtypes of colorectal cancer: an emerging therapeutic opportunity for personalized medicine. *Genes & Diseases* **8**:133–145. DOI: https://doi.org/10.1016/j.gendis.2019.10.013, PMID: 33997160

Ten Hoorn S, de Back TR, Sommeijer DW, Vermeulen L. 2022. Clinical value of consensus molecular subtypes in colorectal cancer: a systematic review and meta-analysis. *Journal of the National Cancer Institute* **114**:503–516. DOI: https://doi.org/10.1093/jnci/djab106, PMID: 34077519

Wang W, Kandimalla R, Huang H, Zhu L, Li Y, Gao F, Goel A, Wang X. 2019. Molecular subtyping of colorectal cancer: recent progress, new challenges and emerging opportunities. *Seminars in Cancer Biology* **55**:37–52. DOI: https://doi.org/10.1016/j.semcancer.2018.05.002, PMID: 29775690